Previous 10 | Next 10 |
Nes Ziona, Israel, July 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it has initiated the design and construction process for a new wholly owned m...
Nes Ziona, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that members of the Company’s management team will participate in A.G.P....
Enlivex Therapeutics (ENLV) announces that the European Patent Office has issued European patent No. 3,258,943 covering Allocetra, the company’s immunotherapy product candidate.The patent is expected to provide added intellectual property protection for therapeutic compositions of Allo...
Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today ...
Nes Ziona, Israel, June 03, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the Jefferies 2021 Virtual Healthcare Conf...
Enlivex Therapeutics shares rise ([[ENLV]] +6.5%) after announcing that the Canadian Intellectual Property Office has issued patent no. 2,893,962 covering Allocetra, the company’s immunotherapy product candidate.The new patent is expected to provide added intellectual property protecti...
Nes-Ziona, Israel, June 01, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced...
Grant provides $1.1 million in non-dilutive funding for 2021 Nes Ziona, Israel, May 18, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis...
Brooklyn ImmunoTherapeutics (BTX) +38%.Regional Health Properties (RHE) +21%.Gaucho Group Holdings (VINO) +15%.Ashford Hospitality Trust (AHT) +15%.Ocugen (OCGN) +13% as COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2.DAVIDsTEA (DTEA) +10%...
Galera Therapeutics (GRTX) +41% on updating data from pancreatic cancer trial.Willamette Valley Vineyards (WVVI) +18%.Nokia Corporation (NOK) +17% on Q1 results.VEREIT (VER) +17% as Realty Income to acquire the company.Enlivex Therapeutics (ENLV) +13%.Pluristem Therapeutics (PS...
News, Short Squeeze, Breakout and More Instantly...
Enlivex Therapeutics Ltd. Company Name:
ENLV Stock Symbol:
NYSE Market:
Enlivex Therapeutics Ltd. Website:
• First study of Allocetra TM in psoriatic arthritis, a chronic inflammatory condition that causes joint pain, swelling and stiffness, affects as many as 30% of people with psoriasis 1 , and has limited treatment options Nes-Ziona, Israel, July 23, 2024 (GLOB...
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern T...
First patient dosed with Allocetra TM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people Thumb osteoarthritis currently has no FDA-approved therapy and no effective long-term treatments Ness-Ziona, Israel, June 24, 2024 (GLO...